Lineage Cell Therapeutics, Inc. Capital Leases, Income Statement, Amortization Expense
Lineage Cell Therapeutics, Inc. (LCTX) reported Capital Leases, Income Statement, Amortization Expense of -$74.00 thousand for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CapitalLeasesIncomeStatementAmortizationExpense · last filed 2016-08-09
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for the quarter ending 2016-06-30 was -$57.00K.
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for the quarter ending 2016-03-31 was -$17.00K.
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for the quarter ending 2015-12-31 was -$28.00K.
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for the quarter ending 2015-09-30 was -$3.00K.
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for fiscal 2015 was -$59.00K.
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for fiscal 2014 was -$26.00K.
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for fiscal 2013 was $0.00.
- Lineage Cell Therapeutics, Inc. capital leases, income statement, amortization expense for fiscal 2012 was $0.00.
| Period end | Capital Leases, Income Statement, Amortization Expense 3 month | Capital Leases, Income Statement, Amortization Expense 3 month as first filed | Capital Leases, Income Statement, Amortization Expense 6 month | Capital Leases, Income Statement, Amortization Expense 9 month | Capital Leases, Income Statement, Amortization Expense 9 month as first filed | Capital Leases, Income Statement, Amortization Expense 12 month | Capital Leases, Income Statement, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2016-06-30 | -$57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$74.00K 10-Q · filed 2016-08-09 | -$102.00K derived: sum of 3 quarters · filed 2016-08-09 | -$105.00K derived: sum of 4 quarters · filed 2016-08-09 | |||
| 2016-03-31 | -$17.00K 10-Q · filed 2016-05-10 | -$45.00K derived: sum of 2 quarters · filed 2016-05-10 | -$48.00K derived: sum of 3 quarters · filed 2016-05-10 | -$62.00K derived: sum of 4 quarters · filed 2016-08-09 | |||
| 2015-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$31.00K derived: sum of 2 quarters · filed 2016-03-15 | -$45.00K derived: sum of 3 quarters · filed 2016-08-09 | -$59.00K 10-K · filed 2016-03-15 | |||
| 2015-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$17.00K derived: sum of 2 quarters · filed 2016-08-09 | -$31.00K 10-Q · filed 2015-11-09 | -$44.00K derived: sum of 4 quarters · filed 2016-08-09 | |||
| 2015-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$28.00K 10-Q · filed 2016-08-09 | -$41.00K derived: sum of 3 quarters · filed 2016-08-09 | -$54.00K derived: sum of 4 quarters · filed 2016-08-09 | |||
| 2015-03-31 | -$14.00K 10-Q · filed 2016-05-10 | -$13.98K 10-Q · filed 2015-05-08 | -$27.00K derived: sum of 2 quarters · filed 2016-05-10 | -$40.00K derived: sum of 3 quarters · filed 2016-05-10 | -$40.00K derived: sum of 4 quarters · filed 2016-05-10 | ||
| 2014-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$26.00K derived: sum of 2 quarters · filed 2016-03-15 | -$26.00K derived: sum of 3 quarters · filed 2016-03-15 | -$26.00K 10-K · filed 2016-03-15 | -$26.21K 10-K · filed 2015-03-11 | ||
| 2014-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$13.00K derived: sum of 2 quarters · filed 2015-11-09 | -$13.00K 10-Q · filed 2015-11-09 | $12.54K 10-Q · filed 2014-11-07 | -$13.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | $0.00 derived: sum of 3 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | |||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 10-K · filed 2016-03-15 | |||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-07 | ||||||
| 2012-12-31 | $0.00 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |